Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

• Status: Active, not recruiting
• Trial end date: 2025-04-01

Summary

Primary Objective:

To determine the long-term safety and tolerability of SAR442168 in RMS participants

Secondary Objective:

To evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging methods

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi